These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 1992188

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evolution and current status of the Orphan Drug Act.
    Asbury CH.
    Int J Technol Assess Health Care; 1992; 8(4):573-82. PubMed ID: 1464479
    [Abstract] [Full Text] [Related]

  • 3. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 4. Do investors value the FDA orphan drug designation?
    Miller KL.
    Orphanet J Rare Dis; 2017 Jun 19; 12(1):114. PubMed ID: 28629392
    [Abstract] [Full Text] [Related]

  • 5. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT.
    Adv Exp Med Biol; 2017 Jun 19; 1031():183-196. PubMed ID: 29214572
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM, Reed SD, Schulman KA.
    Health Aff (Millwood); 2012 Nov 19; 31(11):2528-35. PubMed ID: 23129684
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Orphan drugs: the question of products liability.
    Scharf SF.
    Am J Law Med; 1985 Nov 19; 10(4):491-513. PubMed ID: 3911776
    [Abstract] [Full Text] [Related]

  • 10. The economics of orphan drug policy in the US. Can the legislation be improved?
    Peabody JW, Ruby A, Cannon P.
    Pharmacoeconomics; 1995 Nov 19; 8(5):374-84. PubMed ID: 10160072
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Market incentives and pharmaceutical innovation.
    Yin W.
    J Health Econ; 2008 Jul 19; 27(4):1060-1077. PubMed ID: 18395277
    [Abstract] [Full Text] [Related]

  • 13. Orphan drug development in the United States.
    Groft SC.
    CPJ; 1985 May 19; 118(5):219-22. PubMed ID: 10271306
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Orphan Drug Act Revisited.
    Thomas S, Caplan A.
    JAMA; 2019 Mar 05; 321(9):833-834. PubMed ID: 30768155
    [No Abstract] [Full Text] [Related]

  • 17. Drug legislation. Drug companies divided.
    Gershon D.
    Nature; 1990 May 03; 345(6270):6. PubMed ID: 2330052
    [No Abstract] [Full Text] [Related]

  • 18. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 19. New products highlight ambiguity of orphan drug law.
    Reid B.
    Nat Biotechnol; 2003 Jan 19; 21(1):6-7. PubMed ID: 12511896
    [No Abstract] [Full Text] [Related]

  • 20. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA.
    Am J Clin Oncol; 2016 Apr 19; 39(2):210-3. PubMed ID: 26580246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.